EMA/PE/0000241034 - paediatric investigation plan

Lebrikizumab

Key facts

• Invented name:
  Ebglyss
• Active substance:
  Lebrikizumab
• Therapeutic area:
  Skin and subcutaneous tissue disorders
• Decision number:
  EMA/PE/0000241034
• PIP number:
  EMA/PE/0000241034
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of atopic dermatitis
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  15/05/2025
• Compliance check done:
  Nie

Decision

EMA/PE/0000241034: EMA decision of 15 May 2025 on the acceptance of a modification of an agreed paediatric investigation plan for lebrikizumab (Ebglyss)

Adopted Reference Number: EMADOC-1700519818-2115936